PDCD1 and non-small cell lung carcinoma: Kang et al.44reported that the peripheral interleukin‐6 level at baseline is relevant to the clinical efficacy of anti‐PD‐1 therapy in NSCLC patients, further supporting its utility as a predictor of response.